ClinicalTrials.gg
Active, not recruitingNCT05425940STELLAR-303Updated Jul 17, 2026

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

A Phase 3 interventional study of XL092 and Atezolizumab in Colorectal Cancer, sponsored by Exelixis. Active, not recruiting at 133 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
901
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
170th of 1,932
901 · median 64
Started
2022
with 126 others
Phase 3
117 of 2,339
16 open now
Primary completion
2026-06
later than 89 of 628 live
Registered
1,775th of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 170th largest by enrollment of the 1,932 interventional ones that give a count, is one of 127 that started in 2022, is one of 117 in phase 3, reaches primary completion later than 89 of the 628 other live ones, and was the 1,775th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

413 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with or cytologically confirmed adenocarcinoma of the colon or rectum.

    • Documented rat sarcoma (RAS) status (mutant or wild-type [WT]), by tissue-based analysis.
    • Documented NOT to have microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) CRC by tissue-based analysis.
  • Has received SOC anticancer therapies as prior therapy for CRC and has radiographically progressed, is or intolerant to these therapies.

    • Systemic SOC anticancer therapy if approved and available in the country where the participant is randomized.
    • Radiographic progression during treatment with or within 4 months following the last dose of the most recent approved SOC chemotherapy regimen.
  • according to (RECIST) v1.1 as determined by the Investigator.
  • Available archival tumor material. If archival tissue is unavailable, must provide fresh tumor tissue biopsy prior to randomization.
  • Recovery to baseline or ≤ Grade 1 severity ( [CTCAE] version 5) from adverse events (AEs) related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
  • (ECOG) performance status of 0-1.
  • Adequate organ and marrow function.
  • Fertile participants and their partners must agree to use highly effective methods of during the course of the study and after the last dose of treatment.
  • Females of must not be pregnant at screening.

Key Exclusion Criteria:

  • Prior treatment with XL092, regorafenib, trifluridine/tipiracil, or programmed cell death protein-1/and its ligand (/PD-1) targeting immune checkpoint inhibitors (ICIs).
  • Receipt of a small molecule kinase inhibitor (including agents) within 2 weeks before randomization.
  • Receipt of any type of anticancer antibody therapy, systemic chemotherapy, or hormonal anti-cancer therapy within 3 weeks (or bevacizumab within 4 weeks) before randomization.
  • Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before randomization.
  • Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before randomization.
  • Has uncontrolled, significant intercurrent or recent illness.
  • Major surgery (example, gastrointestinal (GI) surgery, removal or biopsy of brain metastasis) within 4 weeks prior to randomization.
  • Systemic treatment with, or any condition requiring, either (> 10 mg daily prednisone equivalent) or other medications within 14 days prior to randomization.
  • interval calculated by the Fridericia formula (QTcF) > 460 milliseconds (ms) within 10 days before randomization.
  • History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give .
  • Pregnant or lactating females.
  • Inability to swallow study treatment formulation, inability to receive IV administration, or presence of GI condition that might affect the absorption of study drug.
  • Previously identified allergy or to components of the study treatment formulations.
  • Any other active or diagnosis of another malignancy within 2 years before randomization. Exceptions are noted in the protocol.
  • Administration of a live, attenuated vaccine within 30 days before randomization.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
901 participants (actual)

Study arms

  • Experimental
    XL092 + Atezolizumab

    Participants with mCRC will receive XL092 + atezolizumab.

    Drug: XL092 · Drug: Atezolizumab

  • Active comparator
    Regorafenib

    Participants with mCRC will receive active comparator of regorafenib.

    Drug: Regorafenib

Interventions

  • DrugXL092

    Supplied as tablets; administered orally daily.

  • Supplied as 1200 milligrams (mg)/20 milliliter (mL) vials; administered as a 1200 mg intravenous (IV) infusion once in a 3-week cycle (q3w).

    Also known as: Tecentriq®

  • Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle.

    Also known as: Stivarga®

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized Participants

    Time frame: Up to 32 months

  2. Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in Randomized Non-Liver Metastases (NLM) Participants

    Time frame: Up to 32 months

Secondary outcomes

  1. Progression-Free Survival (PFS) as Assessed by the Investigator

    Time frame: Up to 26 months

  2. Duration of Response (DOR) as Assessed by the Investigator

    Time frame: Up to 36 months

  3. Objective Response Rate (ORR) as Assessed by the Investigator

    Time frame: Up to 36 months

  4. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 36 months

  5. Maximum Observed Plasma Drug Concentration (Cmax) of XL092

    Time frame: Predose up to 72 hours postdose

  6. Time to Maximum Observed Plasma Drug Concentration (Tmax) of XL092

    Time frame: Predose up to 72 hours postdose

  7. Number of Participants who Develop Antidrug Antibodies (ADA) Against Atezolizumab

    Time frame: Up to 36 months

07

Study locations

133 sites
  • Exelixis Clinical Site #65
    Jonesboro, Alabama 72401, United States
  • Exelixis Clinical Site #30
    Phoenix, Arizona 85004, United States
  • Exelixis Clinical Site #70
    Tucson, Arizona 85719, United States
  • Exelixis Clinical Site #9
    Duarte, California 91010, United States
  • Exelixis Clinical Site #55
    La Jolla, California 92037, United States
  • Exelixis Clinical Site #77
    Los Angeles, California 90095, United States
  • Exelixis Clinical Site #105
    Orange, California 92868, United States
  • Exelixis Clinical Site #80
    Santa Monica, California 90404, United States
  • Exelixis Clinical Site #5
    Santa Rosa, California 95403, United States
  • Exelixis Clinical Site #82
    Sylmar, California 91342, United States
  • Exelixis Clinical Site #58
    Torrance, California 90505, United States
  • Exelixis Clinical Site #81
    Whittier, California 90602, United States
  • Exelixis Clinical Site #125
    New Haven, Connecticut 06510, United States
  • Exelixis Clinical Site #16
    Miami Beach, Florida 33140, United States
  • Exelixis Clinical Site #60
    Orlando, Florida 32804, United States
  • Exelixis Clinical Site #4
    Marietta, Georgia 30060, United States
  • Exelixis Clinical Site #3
    Joliet, Illinois 60435, United States
  • Exelixis Clinical Site #102
    Indianapolis, Indiana 46250, United States
  • Exelixis Clinical Site #10
    Westwood, Kansas 66205, United States
  • Exelixis Clinical Site #47
    Lexington, Kentucky 40536, United States
  • Exelixis Clinical Site #7
    New Orleans, Louisiana 70112, United States
  • Exelixis Clinical Site #22
    St Louis, Missouri 63141, United States
  • Exelixis Clinical Site #8
    Billings, Montana 59102, United States
  • Exelixis Clinical Site #1
    Omaha, Nebraska 68130, United States
  • Exelixis Clinical Site #15
    Albuquerque, New Mexico 87131, United States
  • Exelixis Clinical Site #11
    New York, New York 10016, United States
  • Exelixis Clinical Site #59
    New York, New York 10029, United States
  • Exelixis Clinical Site #17
    The Bronx, New York 10461, United States
  • Exelixis Clinical Site #74
    Charlotte, North Carolina 28204, United States
  • Exelixis Clinical Site #6
    Cincinnati, Ohio 45219, United States
  • Exelixis Clinical Site #12
    Oklahoma City, Oklahoma 73142, United States
  • Exelixis Clinical Site #75
    Portland, Oregon 97210, United States
  • Exelixis Clinical Site #106
    Philadelphia, Pennsylvania 19107, United States
  • Exelixis Clinical Site #18
    Pittsburgh, Pennsylvania 15212, United States
  • Exelixis Clinical Site #103
    Pittsburgh, Pennsylvania 15232, United States
  • Exelixis Clinical Site #24
    Greenville, South Carolina 29607, United States
  • Exelixis Clinical Site #56
    Chattanooga, Tennessee 37404, United States
  • Exelixis Clinical Site #76
    Nashville, Tennessee 37203, United States
  • Exelixis Clinical Site #133
    Nashville, Tennessee 37232, United States
  • Exelixis Clinical Site #450
    Fairfax, Virginia 22031, United States
  • Exelixis Clinical Site #14
    Roanoke, Virginia 24014, United States
  • Exelixis Clinical Site #13
    Seattle, Washington 98101, United States
  • Exelixis Clinical Site #32
    Seattle, Washington 98104, United States
  • Exelixis Clinical Site #89
    Seattle, Washington 98109, United States
  • Exelixis Clinical Site #2
    Spokane, Washington 99208, United States
  • Exelixis Clinical Site #83
    Albury, 2640, Australia
  • Exelixis Clinical Site #53
    Bankstown, 2200, Australia
  • Exelixis Clinical Site #117
    Bedford Park, 5042, Australia
  • Exelixis Clinical Site #97
    Heidelberg, 3084, Australia
  • Exelixis Clinical Site #19
    Melbourne, 3002, Australia
  • Exelixis Clinical Site #23
    Melbourne, 3021, Australia
  • Exelixis Clinical Site #27
    Port Macquarie, 2444, Australia
  • Exelixis Clinical Site #64
    Woodville South, 5011, Australia
  • Exelixis Clinical Site #43
    Antwerp, 2300, Belgium
  • Exelixis Clinical Site #51
    Brussels, 1200, Belgium
  • Exelixis Clinical Site #35
    Namur, 5000, Belgium
  • Exelixis Clinical Site #52
    Besançon, 25030, France
  • Exelixis Clinical Site #84
    Dijon, 21079, France
  • Exelixis Clinical Site #88
    Herbault, 34298, France
  • Exelixis Clinical Site #71
    Lyon, 69008, France
  • Exelixis Clinical Site #87
    Marseille, 13385, France
  • Exelixis Clinical Site #38
    Paris, 75020, France
  • Exelixis Clinical Site #93
    Suresnes, 92150, France
  • Exelixis Clinical Site #127
    Hanover, Niedersach 30625, Germany
  • Exelixis Clinical Site #109
    Dresden, 01307, Germany
  • Exelixis Clinical Site #113
    Frankfurt am Main, 60488, Germany
  • Exelixis Clinical Site #61
    Hamburg, 20249, Germany
  • Exelixis Clinical Site #63
    Hamburg, 22763, Germany
  • Exelixis Clinical Site #91
    München, 81737, Germany
  • Exelixis Clinical Site #25
    Hong Kong, Hong Kong
  • Exelixis Clinical Site #33
    Hong Kong, Hong Kong
  • Exelixis Clinical Site #128
    Nyíregyháza, Szabolcs-Szatmar-Bereg County 4400, Hungary
  • Exelixis Clinical Site #41
    Budapest, 1097, Hungary
  • Exelixis Clinical Site #129
    Budapest, 1122, Hungary
  • Exelixis Clinical Site #48
    Debrecen, 4302, Hungary
  • Exelixis Clinical Site #122
    Győr, 9024, Hungary
  • Exelixis Clinical Site #57
    Auckland, 1023, New Zealand
  • Exelixis Clinical Site #49
    Dunedin, 9016, New Zealand
  • Exelixis Clinical Site #69
    Hamilton, 3204, New Zealand
  • Exelixis Clinical Site #104
    Wellington, 6021, New Zealand
  • Exelixis Clinical Site #20
    Bydgoszcz, 85-796, Poland
  • Exelixis Clinical Site #68
    Opole, 45-061, Poland
  • Exelixis Clinical Site #26
    Siedlce, 08-110, Poland
  • Exelixis Clinical Site #42
    Tomaszów Mazowiecki, 97-200, Poland
  • Exelixis Clinical Site #31
    Warsaw, 02-507, Poland
  • Exelixis Clinical Site #108
    Almada, 2805-267, Portugal
  • Exelixis Clinical Site #120
    Coimbra, 3000-075, Portugal
  • Exelixis Clinical Site #99
    Guimarães, 4835-044, Portugal
  • Exelixis Clinical Site #131
    Lisbon, 1500-650, Portugal
  • Exelixis Clinical Site #124
    Lisbon, 1649-035, Portugal
  • Exelixis Clinical Site #96
    Lisbon, 400-038, Portugal
  • Exelixis Clinical Site #132
    Singapore, 119228, Singapore
  • Exelixis Clinical Site #100
    Singapore, 168583, Singapore
  • Exelixis Clinical Site #39
    Singapore, 217562, Singapore
  • Exelixis Clinical Site #98
    Singapore, 258499, Singapore
  • Exelixis Clinical Site #94
    Singapore, 329563, Singapore
  • Exelixis Clinical Site #36
    Goyang-si, 10408, South Korea
  • Exelixis Clinical Site #29
    Gyeonggi-do, 14068, South Korea
  • Exelixis Clinical Site #28
    Hwasun, 58128, South Korea
  • Exelixis Clinical Site #37
    Seongnam-si, 13620, South Korea

Showing the first 100 of 133 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E, Fakih M, Asghari G, So J, Stein A, Dubreuil O, Bodnar L, He CS, Wang G, Smith R, Eng C, Saeed A; STELLAR-303 study investigators. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet. 2025 Nov 15;406(10517):2360-2370. doi: 10.1016/S0140-6736(25)02025-2. Epub 2025 Oct 20. PubMed 41130252 ↗
  • Saeed A, Tabernero J, Parikh A, Van den Eynde M, Karthaus M, Gerlinger M, Wang Z, Wang G, Smith R, Hecht JR. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer. Future Oncol. 2024;20(24):1733-1743. doi: 10.1080/14796694.2024.2352276. Epub 2024 Jul 23. PubMed 39041200 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jun 2026, 45 months.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 45 months is close to that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2022
First posted
Jun 21, 2022
StartActual
Sep 7, 2022
Primary completionActual
Jun 16, 2026
CompletionEst.
Jan 31, 2027
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05425940
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Sep 7, 2022
Primary completion
Jun 16, 2026
Completion
Jan 31, 2027 (estimated)
Last update
Jul 17, 2026

Study contacts

Medical Director
study director · Exelixis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion